Proficio Capital Partners LLC acquired a new stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the fourth ...

For more information, see our expert panel. You can buy and sell stocks on the go with top stock trading apps like Charles Schwab, SoFi, and E*TRADE. Stock trading apps provide the convenience of ...

Full Year 2024 Results Key Financial Results Revenue: US$285.5m (up 44% from FY 2023).

It measures a company’s stock price relative to its earnings per share. Calculating the P/E ratio involves dividing the market price per share by the company’s earnings per share. A higher P/E ...

MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), ...

Before you buy stock in MannKind, consider this ... partially offset by improved growth-to-net adjustments, and increased price. As a reminder, as of the fourth quarter of 2024, the sales force ...

MannKind (MNKD) reported $76.78 million in revenue ... analysts estimated about them helps investors better project a stock's price performance. Here is how MannKind performed in the just reported ...

Reported primary endpoint of INHALE-1 for Afrezza in pediatrics Progressed MNKD-101 to Global Phase 3 Completed Phase ... convertible notes due 2026 Utilized a combination of cash and stock to avoid ...